Interestingly, CASP3 and CYP1A1 were previously identified to be related to glioma and used to predict the survival for glioma patients (Chao et al. 2022; Liu et al. 2022b), the high expression of CDK1 is associated with the malignant progression in glioma (Chen et al. 2007; Teng et al. 2022), and mutations in MT-CO1 contribute to brain tumours (Kaneva et al. 2021). Here, CASP3 is linked to central nervous system cancer.